Drugs / ZAMAPORVINT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03447470 | Mar 2019 → Sep 2023 | cancer | Redx Pharma Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04907851 | Dec 2021 → Nov 2023 | cancer | Redx Pharma Ltd | Completed | No outcome recorded |
| Phase 2 | NCT04907539 | Nov 2021 → Apr 2024 | colorectal cancer | Redx Pharma Ltd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-06-28 | Redx Pharma Ltd | Results Redx Reports Encouraging Zamaporvint Phase 2 Data redxpharma.com ↗
Zamaporvint in combination with anti-PD-1, in genetically-selected MSS mCRC patients led to partial responses being observed in ~30% patients, potentially higher than current SOC and in a setting where anti-PD-1 therapy alone is not effective |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-28 | Redx Pharma Ltd | Redx Reports Encouraging Zamaporvint Phase 2 Data redxpharma.com ↗ |
| 2024-06-20 | Redx Pharma Ltd | Redx to Present Zamaporvint Phase2 Data at ESMO GI redxpharma.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZAMAPORVINT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314431 ↗ |
| Known as | RXC004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04907851 ↗ |
| Action | Inhibit | “inhibits porcupine (PORCN)” NCT03447470 ↗ |
| Modality | Small molecule | — CHEMBL5314431 ↗ |
| Route | Oral | “RXC004 is taken orally” NCT03447470 ↗ |
| Target | PORCN | “inhibits porcupine (PORCN)” NCT03447470 ↗ |